CN117209588A - 乙肝表面抗原特异性t细胞受体及其用途 - Google Patents

乙肝表面抗原特异性t细胞受体及其用途 Download PDF

Info

Publication number
CN117209588A
CN117209588A CN202210626787.7A CN202210626787A CN117209588A CN 117209588 A CN117209588 A CN 117209588A CN 202210626787 A CN202210626787 A CN 202210626787A CN 117209588 A CN117209588 A CN 117209588A
Authority
CN
China
Prior art keywords
tcr
seq
ser
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210626787.7A
Other languages
English (en)
Chinese (zh)
Inventor
乌尔丽克·普罗策
卡琳·魏斯基兴
黄延周
金涛
张柯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singapore Star Hand Biopharmaceutical Co ltd
Original Assignee
Singapore Star Hand Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Star Hand Biopharmaceutical Co ltd filed Critical Singapore Star Hand Biopharmaceutical Co ltd
Priority to CN202210626787.7A priority Critical patent/CN117209588A/zh
Priority to JP2024572034A priority patent/JP2025519475A/ja
Priority to CA3258313A priority patent/CA3258313A1/en
Priority to PCT/SG2022/050892 priority patent/WO2023239290A1/en
Priority to AU2022462612A priority patent/AU2022462612A1/en
Priority to IL317429A priority patent/IL317429A/en
Priority to US18/871,858 priority patent/US20260021140A1/en
Priority to KR1020257000133A priority patent/KR20250031233A/ko
Priority to EP22945970.6A priority patent/EP4536695A1/en
Publication of CN117209588A publication Critical patent/CN117209588A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202210626787.7A 2022-06-05 2022-06-05 乙肝表面抗原特异性t细胞受体及其用途 Pending CN117209588A (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202210626787.7A CN117209588A (zh) 2022-06-05 2022-06-05 乙肝表面抗原特异性t细胞受体及其用途
JP2024572034A JP2025519475A (ja) 2022-06-05 2022-12-08 Ｈｂｖ表面抗原特異的ｔ細胞受容体およびその使用
CA3258313A CA3258313A1 (en) 2022-06-05 2022-12-08 HBV SURFACE ANTIGEN-SPECIFIC T-LYMPHOCYTE RECEPTORS AND THEIR USES
PCT/SG2022/050892 WO2023239290A1 (en) 2022-06-05 2022-12-08 Hbv surface antigen specific t cell receptors and uses thereof
AU2022462612A AU2022462612A1 (en) 2022-06-05 2022-12-08 Hbv surface antigen specific t cell receptors and uses thereof
IL317429A IL317429A (en) 2022-06-05 2022-12-08 HBV SURFACE ANTIGEN-SPECIFIC T-CELL RECEPTORS AND THEIR USES
US18/871,858 US20260021140A1 (en) 2022-06-05 2022-12-08 HBV Surface Antigen Specific T Cell Receptors And Uses Thereof
KR1020257000133A KR20250031233A (ko) 2022-06-05 2022-12-08 Hbv 표면 항원 특이적 t 세포 수용체 및 이의 용도
EP22945970.6A EP4536695A1 (en) 2022-06-05 2022-12-08 Hbv surface antigen specific t cell receptors and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210626787.7A CN117209588A (zh) 2022-06-05 2022-06-05 乙肝表面抗原特异性t细胞受体及其用途

Publications (1)

Publication Number Publication Date
CN117209588A true CN117209588A (zh) 2023-12-12

Family

ID=89039487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210626787.7A Pending CN117209588A (zh) 2022-06-05 2022-06-05 乙肝表面抗原特异性t细胞受体及其用途

Country Status (9)

Country Link
US (1) US20260021140A1 (https=)
EP (1) EP4536695A1 (https=)
JP (1) JP2025519475A (https=)
KR (1) KR20250031233A (https=)
CN (1) CN117209588A (https=)
AU (1) AU2022462612A1 (https=)
CA (1) CA3258313A1 (https=)
IL (1) IL317429A (https=)
WO (1) WO2023239290A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214603B2 (en) * 2016-04-27 2022-01-04 The Regents Of The University Of Michigan C3D cellular and acellular vaccines for the prevention and treatment of cancer
CN117624340B (zh) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途

Also Published As

Publication number Publication date
US20260021140A1 (en) 2026-01-22
KR20250031233A (ko) 2025-03-06
CA3258313A1 (en) 2023-12-14
AU2022462612A1 (en) 2025-01-16
IL317429A (en) 2025-02-01
JP2025519475A (ja) 2025-06-26
WO2023239290A1 (en) 2023-12-14
EP4536695A1 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
KR102805266B1 (ko) 종양-특이적 t 세포 수용체를 수득하는 방법
CN112204133B (zh) Car nk细胞
JP6580579B2 (ja) Ｔ細胞受容体を発現する細胞を生産する方法および組成物
EP3469362A1 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
JP2019506154A (ja) 組換えｔ細胞受容体を含む組成物及びライブラリー並びに組換えｔ細胞受容体を使用する方法
CN111196858A (zh) 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
CN117209588A (zh) 乙肝表面抗原特异性t细胞受体及其用途
CN116655794A (zh) 一种靶向t细胞淋巴瘤细胞的免疫细胞及其制备方法和应用
CN111253493B (zh) 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用
CN117777271B (zh) 一种t细胞受体(tcr)及其用途
WO2021250511A1 (ko) Mr1에 결합하는 t-세포 수용체 및 이의 용도
EP4340869A1 (en) Tcr constructs specific for magea4-derived epitopes
CA3202725A1 (en) Ras mutant epitope peptide and t cell receptor recognizing ras mutant
CN117777270B (zh) 一种t细胞受体(tcr)及其用途
JP7806252B2 (ja) Ｄｃａｆ４ｌ２特異的ｔ細胞受容体
CN113929767B (zh) 具有高亲和力的t细胞受体及其用途
CN119855899A (zh) 经修饰的靶向乙肝表面抗原的免疫细胞及其医药用途
CN117304294A (zh) 一种β-catenin突变表位肽及其应用
CN121471339B (zh) 特异性结合her2来源肽段的t细胞受体及其用途
JP7774284B2 (ja) Ｍｒｐ３標的遺伝子改変ｔ細胞
CN121800949A (zh) 一种靶向ccr9的嵌合抗原受体及其应用
CN121779537A (zh) 一种针对mage肽的特异性t细胞受体及其应用
CN120329416A (zh) 识别肿瘤相关抗原的tcr分子及其用途
WO2024243807A1 (zh) 靶向ny-eso-1的高亲和力t细胞受体及其应用
CN118512580A (zh) HBsAg特异性TCR-T细胞与PD-1抑制剂联合在制备治疗HBV感染相关疾病的药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination